CLINICAL TRIALS
ACTION-01 (Phase 1b/III)
Investigator physician : Dr Caroline BOURSIER
Phase 1b/3 randomized, controlled, open-label trial comparing RYZ101 with standard treatment in patients with inoperable, advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET) expressing somatostatin receptors (SSTR+) that progressed after prior treatment with a 177Lu-labeled somatostatin analogue (177Lu-SSA)
Gastroenteropancreatic neuroendocrine tumors (GEP-NET)
This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.
Treatment: RYZ101 (225Ac-DOTATATE)
Study status : Recruiting
Clinical Trial number :
NCT05595460
Funding :
